Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;37(7):2031-3.
doi: 10.2337/dc13-2965. Epub 2014 May 1.

Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes

Andrea K Steck  1 , Fran Dong  2 , Iman Taki  2 , Michelle Hoffman  2 , Georgeanna J Klingensmith  2 , Marian J Rewers  2
Affiliations

Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes

Andrea K Steck et al. Diabetes Care. 2014 Jul.

Abstract

Objective: We explore continuous glucose monitoring (CGM) as a new approach to defining early hyperglycemia and diagnosing type 1 diabetes in children with positive islet autoantibodies (Ab+).

Research design and methods: Fourteen Ab+ children, free of signs or symptoms of diabetes, and nine antibody-negative (Ab-) subjects, followed by the Diabetes Autoimmunity Study in the Young, were asked to wear a Dexcom SEVEN CGM.

Results: The Ab+ subjects showed more hyperglycemia, with 18% time spent above 140 mg/dL, compared with 9% in Ab- subjects (P = 0.04). Their average maximum daytime glucose value was higher, and they had increased glycemic variability. The mean HbA1c in the Ab+ subjects was 5.5% (37 mmol/mol). Among Ab+ subjects, ≥18-20% CGM time spent above 140 mg/dL seems to predict progression to diabetes.

Conclusions: CGM can detect early hyperglycemia in Ab+ children who are at high risk for progression to diabetes. Proposed CGM predictors of progression to diabetes require further validation.

PubMed Disclaimer

Comment in

References

    1. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. TrialNet Natural History Committee. Type 1 Diabetes TrialNet Study Group The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97–104 - PubMed
    1. Stene LC, Barriga K, Hoffman M, et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006;7:247–253 - PubMed
    1. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832–836 - PubMed
    1. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Diabetes Prevention Trial-Type 1 Study Group Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2007;30:38–42 - PubMed
    1. Vehik K, Cuthbertson D, Boulware D, et al. TEDDY, TRIGR, Diabetes Prevention Trial–Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 2012;35:1821–1825 - PMC - PubMed

Publication types